SHPHNasdaqPharmaceutical PreparationsFiscal year ends December 31

Shuttle Pharmaceuticals Holdings, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 24, 2026

$4.72−0.36 (-7.09%)

Close on Oct 19, 2026

Market cap: $4.79M
P/E (TTM): –
Dividend yield: –

Shuttle Pharmaceuticals Holdings, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research & Development	4.05	3.62	3.52	1.05	1.02
General & Administrative	5.67	1.39	1.05	0.47	0.04
Operating Expenses	12	7.70	5.89	2.34	1.74
Total Costs & Expenses	2.40	2.10	0.10	–	–
Operating Income	-12	-7.70	-5.89	-2.34	-1.74
Interest Expense	–	–	2.12	0.92	0.00
Interest & Investment Income	0.00	0.04	0.08	–	–
Other Non-Operating Income	0.20	-1.45	-0.70	-2.65	0.59
Asset Impairment Charges	0.11	–	–	–	–
Gain (Loss) on Investments	–	0.03	0.00	–	–
Pretax Income	–	–	-6.59	-5.00	-1.15
Net Income incl. Noncontrolling Interests	–	-9.54	–	1.69	–
Net Income	-12	-9.14	-6.59	-5.00	-1.15
Preferred Dividends	–	–	–	0.40	0.10
Net Income to Common	–	–	-6.59	-6.75	-1.26
EPS (Basic)(per share)	-71.60	-796.50	-882.50	-1,260.00	-240.00
EPS (Diluted)(per share)	-71.60	-826.00	-882.50	-1,260.00	–
Shares Outstanding (Basic, Weighted)(shares)	0.16	0.01	0.01	0.01	0.00
Shares Outstanding (Diluted, Weighted)(shares)	0.16	0.01	0.01	0.01	0.00
EBITDA	-12	-7.69	–	–	–
Net Interest Income	–	0.10	0.10	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -791.0%

Financial strength

Current ratio: 0.11
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.25
Dividend yield: –